IARTのチャート
IARTの企業情報
| symbol | IART |
|---|---|
| 会社名 | Integra LifeSciences Holdings Corp （インテグラ・ライフサイエンシズ・ホ―ルディングス） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Medical/Dental Instruments |
| 業種 | 医療機器_医療用品_ディストリビュ―タ― 医療関連（Health Care） |
| 概要 | 事業概要 インテグラ・ライフサイエンス・ホールディングズ（Integra LifeSciences Holdings Corporation）は医療技術会社である。同社は外科用インプラントと医療機器の開発、製造、マーケティングに従事する。同社のセグメントには脳神経外科手術室と救命救急部に使用される製品ポートフォリオを含む専門設備を提供する特殊外科手術用ソリューション、差別化軟組織修復および組織再生製品、小さな骨固定と関節置換ソリューションを含む整形外科および組織技術により構成される。同社は硬膜修復、精密器具、組織アブレーションおよび神経的ケア用の製品および溶液を販売する。同社はまた熱傷等の急性創傷と糖尿病性足潰瘍と手術組織修復などの慢性創傷を治療するための再生技術製品を販売する。同社の製品は脳神経外科手術、四肢の再建手術、整形外科および一般手術に使用される。 インテグラ・ライフサイエンシズ・ホ―ルディングスは、医療機器を提供する米国の持株会社。外科用インプラント及び医療機器の開発、製造、販売に従事。主に脳神経外科、神経救命診療、整形外科、脊椎治療などの分野に製品を提供。米国はじめ、カナダ、欧州、中東、アフリカ、中南米、アジア、オ―ストラリア、ニュ―ジ―ランドなどで、世界的に事業を展開。 Integra LifeSciences is a global leader in regenerative tissue technologies and neurosurgical solutions dedicated to limiting uncertainty for clinicians, so they can focus on providing the best patient care. Integra offers a comprehensive portfolio of high quality, leadership brands that include AmnioExcel®, Bactiseal®, CerebroFlo®, Certas® Plus, Codman®, CUSA®, DuraGen®, DuraSeal®, ICP Express®, Integra®, MatriStem UBMTM, MediHoney®, MicroFrance®, PriMatrix®, SurgiMend®, TCC-EZ®, and VersaTru®. |
| 本社所在地 | 311 Enterprise Drive Plainsboro NJ 08536 USA |
| 代表者氏名 | Stuart M. Essig スチュアート・エシグ |
| 代表者役職名 | Independent Chairman of the Board |
| 電話番号 | +1 609-275-0500 |
| 設立年月日 | 32660 |
| 市場名 | NASDAQ National Market System |
| ipoyear | ―年 |
| 従業員数 | 4400人 |
| url | www.integralife.com |
| nasdaq_url | https://www.nasdaq.com/symbol/iart |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） 317.48100 |
| 終値（lastsale） | 61.27 |
| 時価総額（marketcap） | 5216010681.2 |
| 時価総額 | 時価総額（百万ドル） 5327.533 |
| 売上高 | 売上高（百万ドル） 1370.708 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 6620.25 |
| 当期純利益 | 当期純利益（百万ドル） 113.28200 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Integra Lifesciences Holdings Corp revenues increased 34% to $723.3M. Net income increased 30% to $22.4M. Revenues reflect Specialty Surgical Solutions segment increase from $159.9M to $475.6M Orthopedics and Tissue Technologies segment increase from $122.3M to $247.7M United States segment increase from $219.3M to $508.6M Europe segment increase from $32.5M to $103.2M. |
IARTのテクニカル分析
IARTのニュース
Integra LifeSciences Holdings Corporation (IART) Shares Boosted in Q4 2023/03/03 08:57:07 Insider Monkey
ClearBridge Investments, an investment management company, released its “ClearBridge SMID Cap Growth Strategy” fourth quarter 2022 investor letter. A copy of the same can be downloaded here. In the fourth quarter, the strategy outperformed the Russell 2500 Growth benchmark. On an absolute basis, the strategy gained in nine of the 10 sectors it was invested in […]
Integra LifeSciences Looks More Interesting Now 2023/02/23 20:57:14 Seeking Alpha
Integra''s fourth quarter results were in-line but still lackluster, with just 3% organic revenue growth. Click here to see our take on IART stock.
Integra LifeSciences PT Raised to $55 at Piper Sandler 2023/02/23 11:19:19 Investing.com
https://www.investing.com/news/pro/integra-lifesciences-pt-raised-to-55-at-piper-sandler-432SI-3011819
Integra LifeSciences Files Mixed Shelf 2023/02/22 22:43:01 Investing.com
https://www.investing.com/news/assorted/integra-lifesciences-files-mixed-shelf-432SI-3011373
Integra LifeSciences Holdings Corporation (IART) Q4 2022 Earnings Call Transcript 2023/02/22 19:56:05 Seeking Alpha
Integra LifeSciences Holdings Corporation (NASDAQ:NASDAQ:IART) Q4 2022 Earnings Conference Call February 22, 2023 8:30 AM ETCompany ParticipantsChris Ward - Senior Director, Investor…
Integra LifeSciences Looks More Interesting Now 2023/02/23 20:57:14 Seeking Alpha
Integra''s fourth quarter results were in-line but still lackluster, with just 3% organic revenue growth. Click here to see our take on IART stock.
Integra LifeSciences PT Raised to $55 at Piper Sandler 2023/02/23 11:19:19 Investing.com
https://www.investing.com/news/pro/integra-lifesciences-pt-raised-to-55-at-piper-sandler-432SI-3011819
Integra LifeSciences Files Mixed Shelf 2023/02/22 22:43:01 Investing.com
https://www.investing.com/news/assorted/integra-lifesciences-files-mixed-shelf-432SI-3011373
Integra LifeSciences Holdings Corporation (IART) Q4 2022 Earnings Call Transcript 2023/02/22 19:56:05 Seeking Alpha
Integra LifeSciences Holdings Corporation (NASDAQ:NASDAQ:IART) Q4 2022 Earnings Conference Call February 22, 2023 8:30 AM ETCompany ParticipantsChris Ward - Senior Director, Investor…
Integra LifeSciences Holdings Corporation 2022 Q4 - Results - Earnings Call Presentation (NASDAQ:IART) 2023/02/22 15:07:12 Seeking Alpha
The following slide deck was published by Integra LifeSciences Holdings Corporation in conjunction with their 2022 Q4 earnings call.
Integra LifeSciences to Present at 41st Annual J.P. Morgan Healthcare Conference 2022/12/21 22:00:00 GlobeNewswire
PRINCETON, N.J., Dec. 21, 2022 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, announced today that Jan De Witte, president and chief executive officer will present at the 41st Annual J.P. Morgan Healthcare conference on January 11, 2023 at 7:30pm ET.
Breast Reconstruction Market Worth $647 Million by 2026 - Global Trend, Business Strategies, Recent Development 2022/12/16 16:46:00 SBWire
In 2022, Mentor Worldwide LLC (Johnson & Johnson) received the US FDA approved a new MENTOR Memory Gel boost breast implant Northbrook, IL 60062 -- ( SBWIRE ) -- 12/16/2022 -- According to the global research report " Breast Reconstruction Market by Product (Breast implant, Tissue Expander, Acellular Dermal Matrix), Procedure (Immediate, Delayed, Revision), Type (Unilateral, Bilateral), End User (Hospitals, Cosmetology Clinics) - Global Forecast to 2026", published by MarketsandMarkets™, The global breast reconstruction market size is expected to reach USD 647 million by 2026 from USD 567 million in 2021, at a CAGR of 2.7%. The growth in this market is driven by the increasing number of breast reconstruction surgeries and rising incidences of breast cancer. Browse in-depth TOC on "Breast Reconstruction Market" 292 – Tables 45 – Figures 252 – Pages Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=186501593 The rising incidence of breast cancer and the availability of reimbursement for breast reconstruction are major driving factors for the market.
Surgical Retractors Global Market Report 2022: Ukraine-Russia War Impact 2022/12/12 11:08:00 GlobeNewswire
Major players in the surgical retractors market are B. Braun, Becton, Dickinson and Company, Henry Schein Inc. , Integra Lifesciences Holdings Corporation, Johnson & Johnson Private Limited, Medline Industries Inc. Major players in the surgical retractors market are B. Braun, Becton, Dickinson and Company, Henry Schein Inc. , Integra Lifesciences Holdings Corporation, Johnson & Johnson Private Limited, Medline Industries Inc.
Enzymatic Wound Debridement Market to Witness Huge Growth by Key Players: Coloplast Corp, ConvaTec Group PLC, Integra LifeSciences, Paul Hartmann Limited 2022/12/05 16:18:27 OpenPR
The study provides an in-depth analysis of the major market players in the Enzymatic Wound Debridement market. It provides a detailed analysis of each segment and driving factors coupled with growth rate analysis. Furthermore, the report also provides regional analysis